Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS)

• DOI: 10.1111/cas.15871
• Publication Date: 2023-07-01T05:42:07Z
• Authors: Shintaro Shiba; Masaru Wakatsuki; Shingo Toyama; Kazuki Terashima; Hirofumi Uchida; Hiroyuki Katoh; Kei Shibuya; Shohei Okazaki; Yuhei Miyasaka; Tatsuya Ohno; Hiroshi Tsuji
• Keywords: Carbon Ion Radiotherapy; Radiation oncology; Carbon fibers

Abstract Reports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate clinical outcomes C‐ion RT at all Japanese facilities using nationwide cohort data. We reviewed medical records obtain registry data between May 2016 June 2020. Patients (1) as confirmed by histological or diagnostic imaging, (2) ≤3 synchronous metastases time treatment, (3) without active extrahepatic disease, (4) who received metastatic regions curative intent were included in this study. was performed 58.0–76.0 Gy (relative biological effectiveness [RBE]) 1–20 fractions. In total, 102 patients (121 tumors) enrolled The median follow‐up duration 19.0 months. tumor size 27 mm. 1‐year/2‐year overall survival, local control, progression‐free survival rates 85.1%/72.8%, 90.5%/78.0%, 48.3%/27.1%, respectively. No patient developed grade 3 higher acute late toxicity. is a safe effective treatment may be beneficial option multidisciplinary treatment.